HC Wainwright Estimates LifeMD’s Q2 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of LifeMD in a report released on Tuesday, May 26th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.24) for the quarter, down from their prior forecast of $0.06. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for LifeMD’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for LifeMD’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.12) EPS, Q4 2027 earnings at $0.15 EPS and FY2027 earnings at ($0.01) EPS.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The company had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%.

LFMD has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Loop Capital set a $10.00 price target on shares of LifeMD in a research note on Thursday, March 12th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of LifeMD in a research note on Monday, May 4th. Finally, Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, LifeMD has an average rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.59 on Friday. The stock has a market cap of $221.97 million, a P/E ratio of 91.82 and a beta of 2.03. The firm has a fifty day moving average price of $4.16 and a 200 day moving average price of $3.77. LifeMD has a 1-year low of $2.56 and a 1-year high of $15.84.

Hedge Funds Weigh In On LifeMD

A number of large investors have recently bought and sold shares of LFMD. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD during the 4th quarter worth $36,000. Magnus Financial Group LLC purchased a new position in LifeMD during the 4th quarter worth $41,000. R Squared Ltd purchased a new position in LifeMD during the 1st quarter worth $41,000. Jain Global LLC purchased a new position in LifeMD during the 4th quarter worth $45,000. Finally, Quarry LP purchased a new position in LifeMD during the 3rd quarter worth $52,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Trending Headlines about LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on LifeMD and kept its $10 price objective, signaling continued upside potential versus the current share price.
• Positive Sentiment: The firm’s updated models still point to improved profitability later on, including a forecast of $0.15 EPS for Q4 2027, which suggests confidence in LifeMD’s longer-term earnings power.
• Neutral Sentiment: HC Wainwright’s FY2027 estimate of ($0.01) EPS is roughly near breakeven, implying a transition period rather than a clear catalyst either way.
• Negative Sentiment: HC Wainwright lowered FY2026 EPS to ($0.47) from ($0.33), a meaningful downgrade that may pressure shares by reinforcing concerns about near-term losses.
• Negative Sentiment: The analyst also reduced Q2 2026, Q3 2026, and Q4 2026 earnings estimates, indicating softer expectations for LifeMD’s upcoming results.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.